Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5219016
Max Phase: Preclinical
Molecular Formula: C71H108IN23O21S4
Molecular Weight: 1874.96
Associated Items:
ID: ALA5219016
Max Phase: Preclinical
Molecular Formula: C71H108IN23O21S4
Molecular Weight: 1874.96
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](CCCNC(N)=O)C(=O)O)Cc1ccc(O)cc1)CSSC2(C)C
Standard InChI: InChI=1S/C71H108IN23O21S4/c1-34(96)54-64(111)90-45(29-53(101)102)66(113)95-24-8-13-49(95)63(110)88-42(11-6-22-81-69(77)78)58(105)91-47-32-118-117-31-46(85-52(100)30-74)62(109)94-55(65(112)93-54)71(2,3)120-119-33-48(60(107)83-37(25-35-14-17-38(97)18-15-35)28-51(99)84-43(67(114)115)12-7-23-82-70(79)116)92-57(104)40(9-4-20-73)86-59(106)44(27-36-16-19-50(98)39(72)26-36)89-56(103)41(87-61(47)108)10-5-21-80-68(75)76/h14-19,26,34,37,40-49,54-55,96-98H,4-13,20-25,27-33,73-74H2,1-3H3,(H,83,107)(H,84,99)(H,85,100)(H,86,106)(H,87,108)(H,88,110)(H,89,103)(H,90,111)(H,91,105)(H,92,104)(H,93,112)(H,94,109)(H,101,102)(H,114,115)(H4,75,76,80)(H4,77,78,81)(H3,79,82,116)/t34-,37+,40+,41+,42+,43+,44+,45+,46-,47+,48+,49+,54+,55-/m1/s1
Standard InChI Key: WKBMTJBSBLBSSP-TZHKBYJCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1874.96 | Molecular Weight (Monoisotopic): 1873.6018 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):